Spyre Therapeutics
SYRE
SYRE
68 hedge funds and large institutions have $158M invested in Spyre Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
68
Holders Change
-3
Holders Change %
-4.23%
% of All Funds
1.34%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
9
Increased
20
Reduced
16
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$764K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$432K |
| 3 |
SCA
Snowden Capital Advisors
New York
|
+$392K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$389K |
| 5 |
Two Sigma Investments
New York
|
+$379K |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$3.85M |
| 2 |
Nuveen Asset Management
Chicago,
Illinois
|
-$375K |
| 3 |
DAM
Deltec Asset Management
New York
|
-$192K |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$180K |
| 5 |
Squarepoint
New York
|
-$173K |
